Uroplasty’s Neuromodulator Falls Short On Blue Cross Blue Shield Test
This article was originally published in The Gray Sheet
Executive SummaryEvidence does not support Uroplasty’s Urgent PC neuromodulation system, a 510(k)-cleared device for treating overactive bladder and symptoms, as an effective treatment option, according to an assessment by the Blue Cross Blue Shield’s Technology Evaluation Center.
You may also be interested in...
Federal task force issued final recommendations advising CT screening for people at high risk for lung cancer. Stryker acquired Patient Safety Technologies. CMS announced updates on accountable care organizations. More news briefs.